Physician profile
Manar Abdalgani
NPI 1154671873
$11,597.94
in general payments reported to CMS, 2019-2025
12 companies · $8,249 in 2025
The $8,249 reported for 2025 was more than what 87% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $335 · 2020: $2,000 · 2023: $386 · 2024: $627 · 2025: $8,249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,896 · Travel and Lodging: $1,757 · Food and Beverage: $1,609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,896.00 |
| Travel and Lodging | $1,757.46 |
| Food and Beverage | $1,609.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi US Services INC. | $7,986.27 | 2025 | |
| Horizon Therapeutics Plc | $2,000.00 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $470.15 | 2019-2025 | Fasenra, Tezspire |
| Grifols USA, LLC | $304.31 | 2023-2025 | Xembify, Gamunex-C |
| Genzyme Corporation | $233.63 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.13 | 2024-2025 | Cuvitru |
| Amgen INC. | $87.61 | 2023-2024 | Tezspire |
| Novartis Pharmaceuticals Corporation | $55.93 | 2023-2024 | |
| Pharming Healthcare, INC. | $49.15 | 2024 | Ruconest |
| Glaxosmithkline, LLC. | $31.29 | 2024 | Nucala |
| Csl Behring | $20.91 | 2025 | Andembry |
| Endo Pharmaceuticals INC. | $17.56 | 2023 | Supprelin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manar Abdalgani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.